On May 29, 2026, Australia's Therapeutic Goods Administration (TGA) announced a public consultation on proposed amendments to the Poisons Standard that will be considered at the July 2026 meetings of the Advisory Committee on Medicines Scheduling (ACMS) and the Joint Meeting of the Advisory Committee on Chemicals Scheduling (ACCS) and ACMS. The consultation covers scheduling applications and delegate-initiated proposals involving several substances. The ACMS will review proposals relating to loratadine, fexofenadine, and pseudoephedrine, while the Joint ACMS-ACCS meeting will consider a proposal concerning salicylic acid. Public submissions received during the consultation period will be evaluated by the scheduling delegate before an interim decision is made. Stakeholders and members of the public are invited to provide comments on the proposed scheduling amendments outlined in the Public Notice for July 2026. The consultation period opened on May 29, 2026, and will remain open until June 30, 2026. The outcomes of the consultation may inform future amendments to Australia's Poisons Standard and the scheduling controls applicable to the substances under review.

Source
https://consultations.tga.gov.au/tga/scheduling-pre-meeting-notice-acms-joint-j…
Consumer News Region
Consumer News Tags
Therapeutic Goods Administration (TGA); Poisons Standard; Advisory Committee on Medicines Scheduling (ACMS); Advisory Committee on Chemicals Scheduling (ACCS); Public Consultation; Loratadine; Fexofenadine; Pseudoephedrine; Salicylic Acid; Medicines Scheduling